UroSens is on the verge of an exciting international breakthrough with a new diagnostic test for bladder cancer. UroSens develops and commercializes point-of-care tests for cancers of the urinogenitary tract for use in the urology clinic or doctor’s surgery. The initial target is bladder cancer, the fifth most common cancer in the UK with the highest recurrence rate of any malignancy. UroSens’ test requires only a sample of urine which is analysed for the presence of a specific protein using a highly sensitive antibody-based detection system.